Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial-Reference-Cited by-同舟云学术

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

Published:2017-08 Issue:8 Volume:18 Page:1089-1103
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Tap William D,Papai Zsuzsanna,Van Tine Brian A,Attia Steven,Ganjoo Kristen N,Jones Robin L,Schuetze Scott,Reed Damon,Chawla Sant P,Riedel Richard F,Krarup-Hansen Anders,Toulmonde Maud,Ray-Coquard Isabelle,Hohenberger Peter,Grignani Giovanni,Cranmer Lee D,Okuno Scott,Agulnik Mark,Read William,Ryan Christopher W,Alcindor Thierry,del Muro Xavier F Garcia,Budd G Thomas,Tawbi Hussein,Pearce Tillman,Kroll Stew,Reinke Denise K,Schöffski Patrick

Publisher

Elsevier BV

Subject

Oncology

Reference18 articles.

1. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial;Judson;Lancet Oncol,2014

2. PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma;Ryan;J Clin Oncol,2016

3. GeDDiS: a prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas;Seddon;Proc Am Soc Clin Oncol,2015

4. Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule;Benjamin;Cancer,1974

5. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study;Lorigan;J Clin Oncol,2007

Cited by 228 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma;New England Journal of Medicine;2024-09-05

2. New strategies in soft tissue sarcoma treatment;Journal of Hematology & Oncology;2024-09-02

3. The cellular-centered view of hypoxia tumor microenvironment: Molecular mechanisms and therapeutic interventions;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

4. Radiomic-based prediction of lesion-specific systemic treatment response in metastatic disease;Computerized Medical Imaging and Graphics;2024-09

5. Progress in histology specific treatments in soft tissue sarcoma;Expert Review of Anticancer Therapy;2024-08-05